STRATA Skin Sciences Inc. 2025年季度报告

FORM10-Q STRATA SKIN SCIENCES, INC. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(§232.0405 of this chapter)during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller STRATA Skin Sciences, Inc. and SubsidiaryNotes to Condensed Consolidated Financial Statements Note 1The Company: Background STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company dedicated to developing, commercializing andmarketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimerlasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRACexcimer laser system received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of March 31,2025, there were846XTRAC systems placed in dermatologists’ offices in the United States and50systems internationally under theCompany’s recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue ona per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments which, if exceeded, The Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis andleukoderma. The TheraClear® Acne Therapy System (“TheraClear”) combines intense pulsed light with vacuum (suction) for the treatment of mildto moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne. The Company has signed distributor contracts by year as follows: 2019 – Korea, 2020 – Japan, 2021 – China, Israel, Saudi Arabia,Kuwait, Oman, Qatar, Bahrain, UAE, Jordan and Iraq, and 2023 – Mexico and India.We have renewed and/or amended several of Post-COVID-19 PandemicSince March 2020, the global pandemic related to a new strain of coronavirus (“COVID-19”) has negatively impacted business conditions in the industry in which the Company operates, disrupted global supply chains, constrained workforce participation andcreated significant volatility and disruption of financial markets. The pandemic led to the suspension of elective procedures in the U.S.and to the temporary closure of many physician practices, which are the Company’s primary customers. While most physician officeshave reopened, some of the Company’s partner physician practices closed permanently. Accordingly, the COVID-19 pandemic and its Impact of Russia-Ukraine War Prior to the outbreak of the Russia-Ukraine War, Ukraine was the largest exporter of noble gases including neon, krypton, and xenonand has historically been the source of a significant amount of gas supplied to the Company by its contract suppliers. Neon gas isessential to the proper functioning of the Company’s lasers. The Company’s suppliers have been resourceful in continuing to supplygases to the Company but cannot assure the Company that the supply will remain uninterrupted. The reduced supply and ongoing STRATA Skin Sciences, Inc. and SubsidiaryNotes to Condensed Consolidated Financial Statements Impact ofMiddle EastConflict The Company has not seen an impact on its distributors’ businesses in the Middle East due to theMiddle Eastconflict, but cannotpredict the impact should the conflict continue or develop into a larger war. Basis of presentation: Principles of ConsolidationThe condensed consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned, inactive subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation.Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules andregulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. These condensedconsolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurringadjustments and accruals) necessary to fairly present the results of the interim periods. The condense